Browsing Tag
ESR1 Mutation
4 posts
Can Roche’s 62% success rate in breast cancer trials spark the next oncology breakthrough?
Roche’s new oral breast-cancer therapy cut disease-progression risk by up to 62% in late-stage trials. Find out how it could reshape treatment in 2025.
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.
Vepdegestrant delivers Phase 3 success for Arvinas and Pfizer in ESR1-mutant breast cancer
Vepdegestrant shows 43% risk reduction in ESR1-mutant breast cancer vs fulvestrant. Learn how Arvinas and Pfizer aim for FDA filing in H2 2025.